Skip to main content
Erschienen in: Discover Oncology 4/2010

01.08.2010

Breast Ductal Lavage for Assessment of Breast Cancer Biomarkers

verfasst von: Robert Treat Chatterton Jr., Noah P. Parker, Mito Habe-Evans, Michele Bryk, Denise M. Scholtens, Seema A. Khan

Erschienen in: Discover Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Lavage of the ductal systems of the breast provides fluid (ductal lavage fluid, DLF) containing hormones and products of hormone actions that may represent more accurately the composition of the breast than samples collected from blood or urine. The present study was undertaken to assess the presence of potential cancer biomarkers, their variation among individuals at high risk for breast cancer, and differences associated with menopause and tamoxifen treatment. Seventy seven tamoxifen-eligible subjects with a 5-year breast cancer risk estimate (Gail > 1.6%; N = 53) or recently diagnosed breast cancer (N = 24) were offered tamoxifen therapy; those not accepting tamoxifen were under observation only. After 6 months, all subjects underwent ductal lavage (DL) in an unaffected breast. Estradiol (E2), estrone sulfate, androstenedione, dehydroepiandrosterone (DHEA), DHEA sulfate, progesterone, cathepsin D, and epidermal growth factor (EGF) were measured in ductal lavage fluid (DLF) by immunoassays. Data were expressed as the mass of analyte per milligram of protein in DLF and normalized by natural log transformation. With the exception of DHEA, none of the analytes measured were significantly lower in postmenopausal women than in premenopausal women. The mean loge concentration difference in estradiol was 10.9%. Tamoxifen treatment for 6 months did not result in a significantly greater concentration of E2 or in any of the other analytes in DLF of pre- or postmenopausal women. The between-duct variance of the concentration of free steroids within the same breast averaged 51% less than that between subjects, and was similar to that of non-diffusible proteins. The maintenance of estradiol concentrations in the breast after menopause demonstrates the importance of local biosynthesis. The fact that DLF E2 does not reflect the high serum concentrations of E2 during tamoxifen treatment indicates that breast concentrations of estradiol may be under feedback control. Unlike studies of low risk populations, progesterone concentrations were not significantly less in postmenopausal than in premenopausal women. The similarity in variance of free steroids and protein analytes between ducts of a breast indicates little transfer of steroids between lobules.
Literatur
1.
Zurück zum Zitat Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3(1):49–61CrossRefPubMed Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3(1):49–61CrossRefPubMed
2.
Zurück zum Zitat Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefPubMed Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefPubMed
3.
Zurück zum Zitat Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 1:2–10CrossRef Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 1:2–10CrossRef
4.
Zurück zum Zitat Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865CrossRefPubMed Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865CrossRefPubMed
5.
Zurück zum Zitat Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86:159–166CrossRefPubMed Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86:159–166CrossRefPubMed
6.
Zurück zum Zitat Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH (2004) Variation in estradiol, estrogen precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomark Prev 13(6):928–935 Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH (2004) Variation in estradiol, estrogen precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomark Prev 13(6):928–935
7.
Zurück zum Zitat Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2004) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90:1686–1691CrossRefPubMed Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2004) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90:1686–1691CrossRefPubMed
8.
Zurück zum Zitat Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT (2006) Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol Biomark Prev 15(1):39–44CrossRef Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT (2006) Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol Biomark Prev 15(1):39–44CrossRef
9.
Zurück zum Zitat Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86(3–5):245–253CrossRefPubMed Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86(3–5):245–253CrossRefPubMed
10.
Zurück zum Zitat Blankenstein MA, Szymczak J, Daroszewski J, Milewicz A, Thijssen JH (1992) Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 6(1):13–17CrossRefPubMed Blankenstein MA, Szymczak J, Daroszewski J, Milewicz A, Thijssen JH (1992) Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 6(1):13–17CrossRefPubMed
11.
Zurück zum Zitat Thijssen JH, van Landeghem AA, Poortman J (1986) Uptake and concentration of steroid hormones in mammary tissues. Ann NY Acad Sci 464:106–116CrossRefPubMed Thijssen JH, van Landeghem AA, Poortman J (1986) Uptake and concentration of steroid hormones in mammary tissues. Ann NY Acad Sci 464:106–116CrossRefPubMed
12.
Zurück zum Zitat Thijssen JH, Blankenstein MA, Miller WR, Milewicz A (1987) Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 50(1–3):297–306CrossRefPubMed Thijssen JH, Blankenstein MA, Miller WR, Milewicz A (1987) Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 50(1–3):297–306CrossRefPubMed
13.
Zurück zum Zitat Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41CrossRefPubMed Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41CrossRefPubMed
14.
Zurück zum Zitat Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A, Thijssen JH (1992) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41(3–8):891–896CrossRefPubMed Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A, Thijssen JH (1992) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41(3–8):891–896CrossRefPubMed
15.
Zurück zum Zitat Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27CrossRefPubMed Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27CrossRefPubMed
16.
Zurück zum Zitat Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643CrossRefPubMed Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643CrossRefPubMed
17.
Zurück zum Zitat Dooley WC, Ljung B-M, Veronesi U, Cassaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632CrossRefPubMed Dooley WC, Ljung B-M, Veronesi U, Cassaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632CrossRefPubMed
18.
Zurück zum Zitat Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomark Prev 14(11):2620–2627CrossRef Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomark Prev 14(11):2620–2627CrossRef
19.
Zurück zum Zitat Love SM (2005) Re: ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 97(11):857–858PubMed Love SM (2005) Re: ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 97(11):857–858PubMed
20.
Zurück zum Zitat Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488–1491CrossRefPubMed Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488–1491CrossRefPubMed
21.
Zurück zum Zitat Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70(3):421–428CrossRefPubMed Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70(3):421–428CrossRefPubMed
22.
Zurück zum Zitat Kostoglou-Athanassiou I, Ntalles K, Gogas J, Markopoulos C, Evizou-Terzaki V, Athanassiou P, Georgiou E, Proukakis C (1997) Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 47(3):116–120CrossRefPubMed Kostoglou-Athanassiou I, Ntalles K, Gogas J, Markopoulos C, Evizou-Terzaki V, Athanassiou P, Georgiou E, Proukakis C (1997) Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 47(3):116–120CrossRefPubMed
23.
Zurück zum Zitat Gail MH (2001) The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 949:286–291CrossRefPubMed Gail MH (2001) The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 949:286–291CrossRefPubMed
24.
Zurück zum Zitat Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res 2(3):265–273CrossRef Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res 2(3):265–273CrossRef
25.
26.
Zurück zum Zitat Couissi D, Dubois V, Remacle C, Schonne E, Trouet A (1997) Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182, 780. Clin Exp Metastasis 15(4):349–360CrossRefPubMed Couissi D, Dubois V, Remacle C, Schonne E, Trouet A (1997) Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182, 780. Clin Exp Metastasis 15(4):349–360CrossRefPubMed
27.
Zurück zum Zitat Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548CrossRefPubMed Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548CrossRefPubMed
28.
Zurück zum Zitat Gingras S, Cote S, Simard J (2000) Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Mol Endocrinol 14(2):229–240CrossRefPubMed Gingras S, Cote S, Simard J (2000) Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Mol Endocrinol 14(2):229–240CrossRefPubMed
29.
Zurück zum Zitat Purohit A, Singh A, Reed MJ (1999) Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer. Biochem Soc Trans 27(2):323–327PubMed Purohit A, Singh A, Reed MJ (1999) Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer. Biochem Soc Trans 27(2):323–327PubMed
30.
Zurück zum Zitat Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ (2006) The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 248(1–2):199–203CrossRefPubMed Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ (2006) The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 248(1–2):199–203CrossRefPubMed
31.
Zurück zum Zitat Going JJ (2006) Ductal-lobar organisation of human breast tissue, its relevance in disease and a research objective: vector mapping of parenchyma in complete breasts (the Astley Cooper project). Breast Cancer Res 8(4):107–107CrossRefPubMed Going JJ (2006) Ductal-lobar organisation of human breast tissue, its relevance in disease and a research objective: vector mapping of parenchyma in complete breasts (the Astley Cooper project). Breast Cancer Res 8(4):107–107CrossRefPubMed
Metadaten
Titel
Breast Ductal Lavage for Assessment of Breast Cancer Biomarkers
verfasst von
Robert Treat Chatterton Jr.
Noah P. Parker
Mito Habe-Evans
Michele Bryk
Denise M. Scholtens
Seema A. Khan
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Discover Oncology / Ausgabe 4/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-010-0021-y

Weitere Artikel der Ausgabe 4/2010

Discover Oncology 4/2010 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.